Introduction
Fabry disease (FD) is a rare genetic lysosomal storage disease caused by the accumulation of globotriaosylceramide (Gb 3 ), potentially affecting any organ or tissue. The disease causing mutations occur on the GLA gene, located on the X chromosome, thus causing abnormally low or absent levels of alpha galactosidase A (aGAL), an enzyme responsible for metabolizing Gb 3.
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With an X-linked transmission, men are usually significantly affected, while women have a more variable presentation ranging from asymptomatic to as severely affected as males. [2] [3] [4] The process of lyonization dictates that in females, during the first weeks of life, one of the X chromosomes is inactivated at random in all cells. 5 Later in life, as organs grow, there will be compact portions of affected cells alternating with portions of unaffected cells. This results in borderline or only variably reduced levels of aGAL.
Although FD can affect most organs, the involvement of the heart, kidneys, and central nervous system is driving the negative prognosis of this disorder. 6 While some of the clinical signs develop early in life (acroparesthesia can be described as early as 3-5 years old), organ damage is more progressive and does not become clinically relevant until adolescence, due to the slow intracellular accumulation of Gb3. 7 The classic cardiac involvement is a form of hypertrophic cardiomyopathy (HCM), usually described as concentric left ventricular hypertrophy (LVH). Rarely, it can also present as asymmetrical septal or obstructive LVH. 8 The age of onset for full cardiac involvement is strictly dependent on the level of residual aGAL activity related to the genetic variant. 9 In men hypertrophy develops usually after the 3rd or 4th decade of life, while in women the onset of cardiomyopathy is delayed by 10 years. 3 predominant cardiac involvement. These so-called 'cardiac variants' are usually considered to be late-onset. 8, 10 Multiple studies have looked into the frequency of FD among patients with unexplained late-onset HCM and showed a prevalence between 1% and 12%. [11] [12] [13] The importance of correct and early diagnosis of these patients results from the fact that there is a specific enzyme replacement therapy (ERT) for FD, and quite recently chaperone therapy by small molecule migalastat was approved in Europe. 16 The efficacy of ERT was demonstrated by long-term outcome studies like the one published by Germain et al. 6 in 2015, showing that after 10 years of ERT, most patients were event free, while stating that older patients at the start of treatment have less benefits from it. In terms of cardiac disease progression, studies by Weidemann et al. have shown that Fabry cardiomyopathy progression is unchanged by ERT once there is significant myocardial fibrosis. 17, 18 Migalastat has shown a promising reduction in LV mass; 16, 19 however, these results need to be confirmed by larger observational studies. Even though the diagnosis of FD is based on enzyme assay and genetic testing, imaging techniques are crucial in many ways. By firstly establishing the diagnosis of HCM, they may raise a suspicion of FD. Echocardiography and cardiac magnetic resonance (CMR) imaging are useful in evaluating disease progression and determining enzyme treatment indications and evolution under therapy. The present article explores the role of cardiac imaging in all of these aspects.
Echocardiography in Fabry disease
Ultrasonography offers several techniques for the assessment of patients with FD: standard 2D transthoracic echocardiography, conventional Doppler, myocardial deformation evaluation methods such as tissue Doppler and speckle tracking. Three-dimensional echocardiography and transoesophageal echocardiography are rarely needed unless used for other associated conditions.
Cardiac structure
The first objective of echocardiography is to identify the presence of LVH as part of Fabry cardiomyopathy ( Figure 1) . As defined by the European Society of Cardiology guidelines, the diagnosis is based on a maximum LV wall thickness of > _15 mm, which cannot be explained by pressure overload (e.g. arterial hypertension, aortic stenosis). 20 In case of a borderline value of 13-14 mm maximum wall thickness, other elements should be used to guide the diagnosis, including family history, clinical systemic manifestations (e.g. renal, neurological, or skin involvement), electrocardiographic particularities, and multimodality imaging results. Although most classical forms of Fabry cardiomyopathy are represented by a non-obstructive, concentric cardiac hypertrophy, this population can be quite heterogeneous, and sometimes obstructive forms of HCM, or severe asymmetric hypertrophy can also be seen Seldom, echocardiography can detect the presence of a hyperechogenic area in the inferolateral myocardium in the parasternal long and short axis views, corresponding to late contrast in CMR acquisitions ( Figure 3) .
Several studies show that right ventricular hypertrophy (RVH) is a common finding in Fabry cardiomyopathy ( Figure 4) . Niemann et al. 21 found RVH in 53 out of the 75 (71%) patients studied, while Graziani et al. 22 only detected RVH in 31% of their Fabry patients, both groups using echocardiography and defining RVH as RV wall thickness >5 mm. Both studies found a relation between RVH and LVH, also showing no example of RV-only Fabry cardiomyopathy. 21, 22 RV global systolic function was normal and CMR showed no late gadolinium enhancement (LGE) in the RV free wall.
21,23
Papillary muscle hypertrophy has been described as one of the specific features of Fabry cardiomyopathy compared to other aetiologies of HCM, as Niemann et al. showed by measuring papillary muscle (PM) area in the mid-ventricular short axis view ( Figure 5 ). The study compared PM area and a ratio of PM area to LV circumference in patients with concentric LVH of various aetiologies (aortic stenosis, arterial hypertension, amyloidosis, or Friedreich ataxia-associated HCM), with the Fabry group having significantly higher values in both those categories. 24 A cut-off of 3.6 cm 2 for the total PM area and 0.18 for PM/LV circumference ratio was found, but further studies including larger numbers of patients are needed to validate such values. The study also discussed the place of visual impression of PMs hypertrophy in this situation, eyeball screening showing a good specificity and sensitivity 16 .
Cardiac function
Until late stages of the disease, global systolic function as measured by ejection fraction in Fabry cardiomyopathy is preserved. However, longitudinal systolic dysfunction as well as diastolic dysfunction can be noted in these patients. The study of myocardial velocities and deformation using Tissue Doppler and speckle tracking imaging have proven useful for early detection of FD and especially in evaluating patients with certain Fabry diagnosis without LVH, which may help in the decision to start ERT. 25, 26 An early Italian study compared tissue Doppler velocities of patients with Fabry mutations plus LVH (genotype positive/phenotype positive), patients with Fabry mutations without LVH (genotype positive/phenotype negative) and healthy controls, and showed a statistically significant decrease in both systolic and diastolic tissue velocities in patients with Fabry mutation without LVH compared to the healthy controls, 25 suggesting that the finding of both lateral and septal S and e 0 values below 10 cm/s has a high sensitivity and specificity for identifying Fabry patients without LVH ( Figure 6 ). However, the overwhelming sensitivity and specificity reported by this study was not completely confirmed by other groups showing a relatively limited ability of tissue Doppler imaging velocities to detect early LV functional involvement. 27, 28 One of the more specific features of Fabry cardiomyopathy is the presence of basal segment inferolateral wall fibrosis (seen both in pathologic specimens and CMR studies, see below). As mentioned before, the presence of fibrosis was shown to be a predictor for unresponsiveness of the cardiac changes to ERT. 29 Identifying echographic parameters that indicate fibrosis is an important goal for patients who have contraindications for CMR (severe renal failure, metallic implants, or claustrophobia) or in centres where CMR is not available. Krämer et al. 26 recently
showed that global longitudinal strain (GLS) is worst in FD patients with myocardial fibrosis (Figure 7) . Furthermore, the authors found that a segmental longitudinal strain worse than -12.5% (lower in absolute values) is an excellent indicator for fibrosis in that area, while a segmental longitudinal strain better than -16.5% excludes fibrosis in that area. It is worth mentioning that the same study did not find any correlation between fibrosis and thinning of the infero-posterior LV wall. Further research has been done trying to identify different strain parameters that can indicate FD using cardiac ultrasonography. Even though some of these methods require offline analysis, they can be useful for identifying patients with FD among patients presenting with HCM. Thus, Weidemann et al. 30 showed a decade ago that the 'double peak sign' in strain-rate imaging tracings (corresponding to postsystolic shortening of the affected segment) seems to be a reliable tool to diagnose regional fibrosis. Also, a very recent study published by Labombarda et al. 31 demonstrated that circumferential strain (CS) and base-to-apex CS gradient was lower in Fabry patients without LVH compared to normal controls and in Fabry patients with LVH compared to patients with other forms of HCM. 
Echocardiographic follow-up
Follow-up of patients with FD is generally based on national or expert consensus documents. Most of these documents [32] [33] [34] recommend that the echocardiographic follow-up of patients with Fabry cardiomyopathy should be performed every 6-12 months. Periodic echocardiographic evaluation in the same centre is a key component for the assessment of progression by comparing with previous Weidemann et al. evaluated cardiac response to therapy using CMR to categorize patients based on fibrosis presence and extent (mild fibrosis when only one segment was involved and severe fibrosis when at least 2 segments were involved). They reported that in patients without fibrosis, ERT resulted in a significant reduction in LV mass, an improvement in myocardial function (as assessed by systolic radial strain rate), and a higher exercise capacity obtained by bicycle stress exercise. In contrast, patients with mild or severe fibrosis showed only minor reductions in LVH and no improvement in myocardial function or exercise capacity. 29 A more recently published Danish cohort showed no significant changes in LV mass as assessed by echocardiography after a mean follow-up of 8 years under ERT, but Sokolow-Lyon voltage and Cornell product criteria were decreased. 35 As mentioned earlier, the pharmacological chaperone migalastat may be able to reduce LV mass. This was shown in the results of the FACETS and ATTRACT studies. The former compared migalastat with placebo in FD patients that had not received ERT for at least 6 months, while the latter compared migalastat with ERT in patients that had been on ERT for at least 12 months. After follow-up, both studies showed significant decrease in LV mass as measured by echocardiography in patients receiving migalastat vs. placebo or ERT, respectively. 16, 19 In the absence of therapy, in late stages of Fabry cardiomyopathy, LV global systolic function may be affected by decreasing LV ejection fraction associated with worsening heart failure symptoms and signs. 1 
Cardiac magnetic resonance imaging
In addition to being a useful tool for measuring ventricular dimensions, wall thickness and LV mass with higher accuracy than echocardiography, CMR offers the unique possibility for tissue characterization with depiction of pathologic myocardial processes such The added value of CMR consists in the detection of sphingolipid accumulation, oedema, and interstitial fibrosis. CMR is able to evaluate the various staged changes in the myocardium both by native T1 mapping, which reflects myocardial disease involving the myocyte and interstitium, as well as by gadolinium-based assessment of the extracellular volume fraction (ECV), reflecting interstitial disease. 37 Myocardial oedema can be evaluated either by the classic T2 weighted sequences or with the newest T2 mapping sequences, both assessing the T2 myocardial relaxation time, which is influenced by the amount of water content in the tissue. The presence of fibrosis can be assessed either by the amount and distribution of the LGE following contrast agents administration (able to describe focal fibrosis) or by quantifying the native and post-contrast T1 myocardial relaxation time with the new T1 mapping methods (dedicated to describe diffuse, interstitial fibrosis).
Pre-and post-contrast T1-mapping techniques with quantification of ECV have been developed and validated for evaluation of diffuse myocardial disease. Particularly native T1 measurements are of interest in FD as they reflect not only the extracellular but also the intracellular space, where the lipid depositions are found. 38 Thompson et al., report significantly reduced myocardial native (non-contrast) values in Fabry patients likely reflecting increased glycosphingolipid accumulation, when compared with controls or patients with other causes of concentric LVH. However, the myocardial ECV in FD is similar to healthy subjects. Therefore, non-contrast T1 mapping has the potential to be used as a screening tool for Fabry in patients with unexplained LVH. 39 Moreover, native T1 reduction prior to the onset of LVH was described and appeared to be associated with early LV functional changes detected by echocardiography. 40 The British CMR group led by James Moon published a series of studies on the same topic. 36, 41 One of these studies tried to correlate T2-mapping, a technique sensitive to inflammation and oedema, to T1-mapping and LGE-CMR findings in Fabry patients vs. sarcomeric HCM, chronic myocardial infarction, and controls. They could demonstrate that Fabry patients show in addition to lower global myocardial native T1 values, abnormally high native T1 and T2 values strictly confined to LGE-positive areas. More interestingly, the most reliable predictor for troponin levels was T2 time in the basal inferolateral wall. Hence, the authors hypothesize that inflammation plays a role in the genesis of myocardial damage in Fabry (Figure 8 ).
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Further work aimed to relate structural and functional myocardial characteristics in consecutive Fabry patients by means of native T1 mapping and feature tracking CMR-derived strain, respectively. This study showed that native T1 values correlated stronger with LV mass than CMR-derived longitudinal strain, emphasizing the potential use of native T1-mapping in the early detection of cardiac involvement and guidance of therapy timing. 42 A segment-by-segment comparison of native T1 values in patients with Fabry found that different segments are affected by a varying degree of native T1 shortening with the highest differences between Fabry and HCM confined to the inferior and inferoseptal regions. 43 Therefore, the authors conclude that segment-specific T1 cut-off values might allow a better characterization of myocardial disease in these patients. The pattern and location of myocardial LGE contribute to the discrimination between different types of non-ischaemic cardiomyopathies. 44 In FD, the characteristic localization of LGE is in the basal segment of the inferolateral LV wall, usually with an intramural pattern ( Figure 9 ). However, atypical scar patterns have been described in up to a quarter of Fabry patients, either in association with the inferolateral scar, or in the context of asymmetrical LV hypertrophy. 45 Koeppe et al. showed that regional differences of LV hypertrophy and wall thickening correspond to the distribution of LGE. Even if the exact molecular mechanisms remain unclear, the authors hypothesize that myocardial fibrosis could trigger In addition to the diagnostic contribution of the patterns of fibrosis, increasing evidence is accumulating regarding the prognostic role of LGE in FD and on possible treatment implications. According to Krämer et al., 18 progression of fibrosis in LGE-CMR was the only independent predictor for the occurrence of malignant ventricular arrhythmias including SCD in Fabry patients. Also, the presence of fibrosis was associated with the risk of arrhythmic events in a recently published systematic review. 47 It has been shown that LGE presence and extent in CMR might play a critical role in the decision of administering ERT, showing that the presence of fibrosis is a predictor for an unsatisfactory response to ERT, regarding improvement of ventricular hypertrophy and function. 17 However, excluding patients from ERT on the basis of the presence of fibrosis alone remains debatable, not only that therapy can halt evolution of cardiac disease, but also with respect to the benefit of other involved organs. Moreover, novel research suggests that CMR can help stage cardiac involvement progression, which can be divided in three stages using native T1 values, LVH, and LGE. Thus, T1 starts decreasing in childhood and drops below threshold levels in adulthood, followed by LVH (mostly in men), inflammation, and LGE localized mainly in the inferolateral wall. 48 This may occur before LVH in women, which corresponds to the earlier observation of Niemann et al. 49 that, in contrast to male patients, the loss of myocardial function and the development of fibrosis do not necessarily require myocardial hypertrophy in female patients with FD. The final stage consists of extensive LGE, LV impairment, and normalization of T1 values in men with ample LVH. 48 Cardiac scintigraphy and positron emission tomography imaging studies
Recent research was done on 123 I-metaiodobenzylguanidine (MIBG) scintigraphy (method which shows sympathetic neuronal damage). A small study compared MIGB uptake and CMR findings in five FD patients, showing that MIGB uptake was significantly lower in the area of LGE, but two patients without LGE also showed localized low MIGB uptake. 50 A similar, but larger study included 25 FD patients, who were divided into three groups: no LGE or MIBG abnormalities; no LGE, but low MIBG uptake; LGE present and low MIBG uptake.
LGE area correlated with low MIBG uptake in the same area. As seen in the previously presented study, there were patients with no detectable CMR abnormalities but with low MIBG uptake. 51 Based on the results of this research, it is likely that neuronal damage evaluated by MIBG scintigraphy precedes visible structural cardiac involvement in FD. For more than 10 years, positron emission tomography (PET) has been used to assess coronary microvascular dysfunction in Fabry patients using dipyridamole-induced maximal blood flow. Earlier studies demonstrated that FD causes abnormal coronary function with low flow reserve and no improvement after 12 months of ERT. [52] [53] [54] A more recent study compared coronary microvascular function in 30 FD patients and 24 healthy controls, concluding that the marked alteration in coronary microvascular function in FD patients is not dependent on LVH or gender and that it may be the only sign of cardiac involvement in some patients. 54 Nappi et al. looked into the feasibility of using simultaneous PET/magnetic resonance (MR) in early detection of cardiac involvement in FD. Thirteen FD patients without apparent cardiac disease underwent simultaneous PET/MR after fludeoxyglucose 18 F (FDG) administration; of these, four patients that had LGE and positive short inversion time inversion recovery (STIR) sequences, also had FDG uptake in the same region. Of the others, only two had FDG focal uptake without LGE or specific STIR. This study showed that inflammation detected by FDG PET/MR imaging might be able to detect early cardiac involvement in FD. 55 
Synthesis of imaging algorithms
Based on current knowledge of characteristic features found in Fabry cardiomyopathy, testing for FD is indicated when presence of LV hypertrophy is associated to other imaging red flags ( Figure 10 , Table 1 ). Clinical suspicion is based on diagnostic clues like association of chronic kidney disease in the absence of alternative aetiology, proteinuria, early stroke, or hear loss, angiokeratoma, either in the index patient or in relatives. Early echocardiographic signs of cardiomyopathy can be represented by low myocardial velocities, low LV GLS, mild LV, or RV hypertrophy. As explained above, LGE presence as well as reduced T1 can be seen in patients with FD even before LVH develops.
All patients with diagnosed FD should undergo a comprehensive baseline echocardiographic evaluation, followed by periodic echocardiography assessment (annual or when new cardiac symptoms occur). Also, CMR should be performed at diagnosis in order to obtain detailed data on LV mass and cardiac function, as well as myocardial structure (scar presence and extension). Non-contrast (native) T1 mapping can be particularly useful in patients with severe renal failure for whom contrast use is prohibited. A recently published expert opinion stated that CMR techniques with LGE and evaluation of tissue characteristics should also be used in monitoring patients, unless contraindicated by severe kidney impairment or the presence of an implanted cardiac device. 56 The place of nuclear imaging tests in the clinical care of Fabry patients still needs exploration.
Conclusions
The current review emphasizes the importance of imaging techniques for the early diagnosis, treatment decision, and finally improvement of patient outcomes. While echocardiography remains the cornerstone for first evaluation and follow-up, more advanced imaging methods have become indispensable in evaluating disease progression and enzyme treatment start and discontinuation. The recent research into new imaging techniques will likely influence future FD guidelines. Considering the rarity of this disease, it is indicated that all patients should be evaluated in expert centres. 
